CACNA1D Protein
Introduction
Cacna1D Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background: #2c3e50; color: white; text-align: center;">CACNA1D Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Calcium Voltage-Gated Channel Subunit Alpha1 D (Cav1.3)</td></tr>
<tr><td><strong>Gene</strong></td><td>[CACNA1D](/genes/cacna1d)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q01658](https://www.uniprot.org/uniprot/Q01658)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~245 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cell membrane, dendritic shafts, presynaptic terminals</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Voltage-gated calcium channel (Cav1) family</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Overview
Mermaid diagram (expand to render)
CACNA1D encodes the alpha-1D subunit of L-type voltage-gated calcium channels, known as Cav1.3. These channels mediate calcium influx in response to membrane depolarization and are expressed in [neurons](/entities/neurons), cardiac pacemaker cells, and endocrine cells. Cav1.3 channels have unique properties including low-voltage activation and prolonged current kinetics.
Structure
Cav1.3 is a large transmembrane protein consisting of:
- Four homologous domains (I-IV), each with 6 transmembrane segments
- Voltage sensor in segments S1-S4 of each domain
- Pore-forming region in segments S5-S6
- Large intracellular loops between domains
- C-terminal tail with calmodulin binding sites
Normal Function
Cav1.3 channels play important roles in:
- Dendritic calcium signaling
- Gene transcription (via calcium-dependent pathways)
- Neurotransmitter release
- Cardiac pacemaker activity
- Hormone secretion from endocrine cells
Unlike other L-type channels (Cav1.2), Cav1.3 activates at more negative voltages and shows slower inactivation, making it particularly important for neuronal signaling at near-threshold potentials.
Role in Disease
Parkinson's Disease
Gain-of-function mutations in CACNA1D have been associated with PD risk. Increased calcium influx through Cav1.3 channels may contribute to dopaminergic neuron vulnerability through:
- Elevated oxidative stress
- Mitochondrial dysfunction
- Triggered cell death pathways
Alzheimer's Disease
Cav1.3 dysregulation contributes to calcium homeostasis alterations in AD. Altered channel function may affect amyloid processing and [tau](/proteins/tau) pathology.
Amyotrophic Lateral Sclerosis
Motor neurons show altered Cav1.3 expression, potentially contributing to excitotoxic vulnerability.
Primary Aldosteronism
Gain-of-function mutations cause constitutive channel activity, leading to increased aldosterone secretion.
Therapeutic Targeting
Current therapeutic approaches include:
- Calcium channel blockers: Dihydropyridines (nifedipine, amlodipine), phenylalkylamines (verapamil), benzothiazepines (diltiazem)
- Cav1.3-selective blockers: Developed to target neuronal Cav1.3 while sparing cardiovascular Cav1.2
- State-dependent blockers: Preferentially bind to inactive states
Key Publications
<sup>[1]</sup> Cav1.3 calcium channels and neuronal survival. Cell Calcium. 2014.<sup>[2]</sup> CACNA1D mutations in primary aldosteronism. Nat Genet. 2013.<sup>[3]</sup> Calcium channel blockers in PD therapy. Neuropharmacology. 2015.
See Also
- [Genes/CACNA1D](/genes/cacna1d)
- [Diseases/Parkinson's Disease](/diseases/parkinsons-disease)
- [Diseases/Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mechanisms/Synaptic Dysfunction Pathway](/mechanisms/synaptic-dysfunction-pathway)
External Links
- [UniProt](https://www.uniprot.org/uniprot/Q01658)
- [NCBI Protein](https://www.ncbi.nlm.nih.gov/protein/Q01658)
- [PDB](https://www.ebi.ac.uk/pdbe/search/?q=Q01658)
Channel Gating and Regulation
CACNA1D channels are regulated by multiple mechanisms:
- Voltage dependence: Typical L-type channel activation around -30 to -20 mV
- Calcium-dependent inactivation (CDI): Mediated by calmodulin binding to IQ motif
- Voltage-dependent inactivation (VDI): Slower, independent of calcium
- Phosphorylation: PKA phosphorylation increases current amplitude
- Beta subunit interaction: Essential for proper trafficking and function
- Alternative splicing: Multiple splice variants with distinct properties
Pathogenic Mutations
Gain-of-function mutations in CACNA1D cause:
- Primary aldosteronism, seizures, and neurological abnormalities (PASNA)
- Missense mutations: p.V1333L, p.I750M, p.F767L
- Cause channel hyperactivity
- Lead to aldosterone overproduction and neurological symptoms
- Bradycardia: Severe heart block in some patients
- Developmental delays: Due to calcium dysregulation in neurons
Loss-of-function variants are associated with:
- Bipolar disorder
- Autism spectrum disorders
- Neurodevelopmental delays
Therapeutic Targeting
| Drug | Mechanism | Status |
|------|-----------|--------|
| Dihydropyridines (nifedipine, amlodipine) | L-type channel blockers | Approved |
| Verapamil, diltiazem | Non-dihydropyridine CCBs | Approved |
| BTZ-043 | Specific Cav1.3 blocker | Research |
| CaV1.3-selective compounds | ReduceRunner selectivity | Preclinical |
Research Directions
- Channelopathy studies: Understanding how mutations cause disease
- Selective blockers: Developing Cav1.3-selective compounds to avoid cardiac side effects
- Gene therapy: AAV-mediated expression of dominant-negative channels
- iPSC models: Patient-derived neurons to study disease mechanisms
Background
The study of Cacna1D Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
<sup>[1]</sup> Cav1.3 calcium channels and neuronal survival. Cell Calcium. 2014.<sup>[2]</sup> CACNA1D mutations in primary aldosteronism. Nat Genet. 2013.<sup>[3]</sup> Calcium channel blockers in PD therapy. Neuropharmacology. 2015.
Pathway Diagram
The following diagram shows the key molecular relationships involving CACNA1D Protein discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)